Bioequivqlence of Gabarep Tablet to Neurotin Tablet (Gabapentin 800 mg)

가바렙정 (가바펜틴 800 mg)의 생물학적 동등성 평가

  • Published : 2008.08.20


The aim of the present study was to evaluate the bioequivalence of two gabapentin preparations. We used Neurontin tablet 800 mg (Pfizer Korea Inc.) as a reference drug for bioequivalence of Gabalep tablet 800 mg (Chong Kun Dang Pharmaceutical Co., Korea), and performed this whole study according to the guidelines of Korea Food and Drug Administration (KFDA). Twenty five healthy male volunteers were administered with each drug in a randomized $2{\times}2$ cross-over study with one week washout interval. After drug administration, blood was taken at predetermined time intervals ($0{\sim}24$ hours) and the concentrations of gabapentin in serum were determined using an high performance liquid chromatography-tandem mass spectrometer (LC-MS/MS) employing electrospray ionization technique and operating in multiple reaction mornitoring (MRM). The analytical method was validated in specificity, accuracy, precision and linearity. The phar-macokinetic parameters such as AUCt and Cmax were calculated and ANOVA test was utilized for the statistical analysis of the parameters using logarithmically transformed AUCt and Cmax. $Mean{\pm}SD$. of AUCt and Cmax value for reference drug and test drug were $29.94{\pm}9.23\;({\mu}g/mL{\cdot}hr)$ and $3.12{\pm}1.11\;({\mu}g/mL{\cdot}hr)$, and $31.48{\pm}9.77\;({\mu}g/mL{\cdot}hr)$ and $3.15{\pm}1.03\;({\mu}g/mL)$, respectively. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of log(0.8) to log(1.25) for AUCt and Cmax, respectively. These results indicate that Gabalep tablet 800 mg is bioequivalent to Neurontin tablet 800 mg.



  1. S.J. Czuczwar and K. Przesmycki, Felbamate, gabapentin and topiramate as adjuvant antiepileptic drugs in experimental models of epilepsy, Polish Journal of Pharmacology, 53, 65-68 (2001)
  2. J.A. Dougherty and D.H. Rhoney, Gabapentin : a unique anti-epileptic agent, Neurological Research, 23, 821-829 (2001)
  3. S. Towanabut, L. Rungreangyingyod and C. Suthisisang, Efficacy and safety of gabapentin as an add-on therapy in refractory partial epileptic patients, Journal of the Medical Association of Thailand, 84, 554-561 (2001)
  4. N.S. Gee, The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel, Journal of Biological Chemistry, 271, 5768-5776 (1996)
  5. K.M. Kelly, Gabapentin. Antiepileptic mechanism of action, Neuropsychobiology, 38, 139-144 (1998)
  6. D.M. Rock, K.M. Kelly and R.L. Macdonald, Gabapentin actions on ligand-and voltage-gated responses in cultured rodent neurons, Epilepsy Research, 16, 89-98 (1993)
  7. G. Gatti, Plasma gabapentin concentrations in children with epilepsy: influence of age, relationship with dosage, and preliminary observationson correlation with clinical response, Therapeutic Drug Monitoring, 25, 54-60 (2003)
  8. Z. Zhu and L. Neirinck, High-performance liquid chromatographic method for the determination of gabapentin in human plasma, Journal of Chromatography. B., 779, 307- 312 (2002)
  9. 식품의약품안전청 고시 제2007-65호, 생물학적동등성 시험기 준 (2007. 09. 20)